Marty Makary: Surgeon, Author, and Controversial FDA Commissioner

Early Life and Career

Marty Makary is a British-American surgeon and professor at Johns Hopkins University, renowned for his expertise in medicine, public health, patient safety, and healthcare reform. He has authored influential books like The Price We Pay, which critiques the inefficiencies and high costs of the U.S. healthcare system Source 1 Source 5.

FDA Nomination and Confirmation

On March 6, 2025, President Donald Trump nominated Makary to lead the FDA. He was confirmed as the 27th Commissioner on March 25, 2025, via a bipartisan Senate vote, focusing on drug approvals, medical device safety, and public health policies Source 3 Source 5.

Tenure and Challenges

Makary’s tenure faced intense political scrutiny, with accusations of biased decisions influenced by politics. He endured pressure from abortion rights advocates, industry leaders, and media outlets like The Atlantic, yet continued public engagements amid uncertainties Source 2 Source 9 Source 10.

Resignation and Aftermath

Makary resigned in May 2026 after a tumultuous period, the fourth high-profile departure. Trump approved a firing plan; he was replaced by acting commissioner Kyle Diamantas. Coverage appeared in Politico, Reuters, NBC News, and CBS News Source 4 Source 6 Source 7 Source 8.

FAQ

Who is Marty Makary?

Marty Makary is a British-American surgeon, professor, author, and former FDA Commissioner known for his work on healthcare reform and patient safety Source 1.

When was Marty Makary appointed FDA Commissioner?

He was nominated on March 6, 2025, and confirmed by the Senate on March 25, 2025, as the 27th Commissioner Source 3.

Why did Marty Makary resign from the FDA?

Makary resigned in May 2026 amid controversies over political influences on agency decisions, pressure from advocates, and a Trump-approved firing plan Source 4 Source 7.

What are some of Marty Makary’s notable contributions?

As a Johns Hopkins professor, he authored books critiquing healthcare costs and inefficiencies, and as FDA head, he aimed to enhance drug safety and public health policies Source 1 Source 5.

Who replaced Marty Makary at the FDA?

Kyle Diamantas was appointed as acting FDA Commissioner following Makary’s resignation Source 8.

What criticisms did Marty Makary face during his tenure?

Critics, including The Atlantic, accused him of allowing political preferences to undermine FDA integrity, leading to calls for his dismissal from multiple directions Source 9 Source 10.